sangell3

Dendreon: Revisiting the Risk/Reward Scenario

Indeed, we are talking a acne, toenail fungus or in the case of ISPH a 'dry eye' treament here. Therefore any concerns over 'efficacy' are mitigated. For the FDA to delay Provenge puts them in much the same bind as that Virginia Tech president got in by failing to issue a campus 'lockdown' after the first murders. In the event Provenge is ultimately approved the delay will have caused many thousands of deaths!

The public will want someone's head on a platter for stalling the release of a treatment that was known to be safe yet, because it was not made available dear old Dad died! The bureaucratic instinct is to play it safe, the medical need is compelling and there are thousands of AIPC patients will nothing to lose. Tell me
how the FDA is going to issue an 'approvable letter' again?